1	Article summary line: Several commercially available SARS-CoV-2 ELISAs show limited
2	specificity when applied to serum panels of African origin.
3	
4	Running title: SARS-CoV-2 IgG ELISA specificity
5	
6	Keywords: SARS-CoV-2, seroepidemiologic studies, immunoglobulin G, Enzyme-Linked
7	Immunosorbent Assay, specificity, Africa
8	
9	Title:
10	Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum
11	samples of African origin
12	
13	Authors:
14	Petra Emmerich, Carolin Murawski, Christa Ehmen, Ronald von Possel, Neele Pekarek, Lisa
15	Oestereich, Sophie Duraffour, Meike Pahlmann, Nicole Struck, Daniel Eibach, Ralf
16	Krumkamp, John Amuasi, Oumou Maiga-Ascofare, Raphael Rakotozandrindrainy, Danny
17	Asogun, Yemisi Ighodalo, Simone Kann, Jürgen May, Egbert Tannich, Christina
18	Deschermeier
19	
20	Affiliations:
21	Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (P. Emmerich,
22	C. Murawski, C. Ehmen, R. von Possel, N. Pekarek, L. Oestereich, S. Duraffour,
23	M. Pahlmann, N. Struck, D. Eibach, R. Krumkamp, J. May, E. Tannich, C. Deschermeier)
24	University of Rostock, Rostock, Germany (P. Emmerich)
25	German Center for Infection Research (DZIF), Hamburg – Lübeck – Borstel – Riems,
26	Germany (L. Oestereich, S. Duraffour, M. Pahlmann, N. Struck, D. Eibach, R. Krumkamp,
27	O. Maiga-Ascofare)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 28 Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana (J. Amuasi,
- 29 O. Maiga-Ascofare)
- 30 University of Antananarivo, Antananarivo, Madagascar (R. Rakotozandrindrainy)
- 31 Irrua Specialist Teaching Hospital, Irrua, Nigeria (D. Asogun, Y. Ighodalo)
- 32 Medical Mission Institute, Würzburg, Germany (S. Kann)
- 33 National Reference Centre for Tropical Pathogens, Hamburg, Germany (E. Tannich)

34

- 35 **Corresponding author:** Christina Deschermeier
- 36 Mailing address: Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Str. 74,
- 37 20359 Hamburg
- 38 Email address: descherm@bnitm.de
- 39 **Phone number:** +49 (40) 42818-438
- 40 **ORCiD ID:** 0000-0002-8309-7877

41 ABSTRACT

42 Specific serological tests are mandatory for reliable SARS-CoV-2 seroprevalence studies but 43 assay specificity may vary considerably between populations due to interference of immune 44 responses to other pathogens. Here, we assess the false positive rates obtained with four 45 commercially available IgG ELISAs in serum/plasma panels originating from three different 46 African countries.

47

By November 1st 2020, 1,324,258 laboratory-confirmed SARS-CoV-2 infections and 29,785 deaths caused by COVID-19 have been reported from the WHO Africa region (1). Currently, community transmission is observed in almost all African countries including Tanzania, Ghana, Madagascar, Nigeria, Kenya, South Sudan, Burundi, and Uganda (1). To correctly determine the actual exposure of the population to SARS-CoV-2 and to draw reliable conclusions on morbidity and case fatality rates, highly sensitive and specific serological tests are mandatory.

55 Up to now, a plethora of ELISA tests for detection of anti-SARS-Cov-2 antibodies has been 56 developed and commercialized (2, 3). Although performance data for several of these assays 57 have been rapidly communicated by different laboratories (4-7), still only few reports are 58 available on the applicability of these tests on African serum panels (8, 9). Here, assay 59 specificity may be challenged by previous or current infections with other endemic pathogens 50 like other coronaviruses (10), Dengue virus (11), or *Plasmodium spp. (12)*.

61

62 THE STUDY

To assess the specificities of commercially available SARS-CoV-2 IgG ELISA tests in sample panels of different origin, *a priori* SARS-CoV-2 IgG negative sample panels (**Table 1**) collected from symptom-free donors before 2019 in Africa (Ghana, Madagascar, Nigeria), South America (Colombia) and Europe (Germany) were analyzed with the Euroimmun Anti-SARS-CoV-2-NCP IgG ELISA (Euroimmun, Germany), the Euroimmun Anti-SARS-CoV-2 IgG ELISA (Euroimmun, Germany), the EDI[™] Novel Coronavirus COVID-19 IgG ELISA

(Epitope Diagnostics, US), and the Mikrogen *recom*Well SARS-CoV-2 IgG ELISA (Mikrogen,
Germany) (**Appendix Table 1**). Assays were performed and evaluated according to the
manufacturers' instructions.

72 While IqG ELISA specificities where good to excellent for pre-COVID-19 sample panels 73 originating from Colombia, Madagascar, and Germany, increased false positive rates were 74 observed in a priori SARS-CoV-2 IgG negative sera from Ghana and Nigeria (Figure 1, 75 **Table 2**). Thereby, the index values obtained with the Euroimmun NCP IgG ELISA and the 76 EDI^{TM} IgG ELISA, both employing recombinant nucleocapsid protein (NCP) as antigen, 77 showed a clear correlation (Appendix Figure 1A, 1C, 1E, 1G), while only 15 samples 78 (Ghana: n=7, Nigeria: n=8), were concordantly classified as positive by both the NCP-based 79 and the spike/S1-based Euroimmun IgG ELISA (Appendix Figure 1B, 1D, 1F, 1H, Figure 80 2A). For all 15 sera, IgG immunofluorescence testing using SARS-CoV-2-infected Vero cells 81 (13) was negative, and no or only weak inhibition of receptor binding was observed in a 82 SARS-CoV-2 surrogate virus neutralizing test (sVNT, Genscript, US) (Figure 2A).

One possible cause of the observed limited specificity of SARS-CoV-2 IgG ELISAs may be cross-reaction with antibodies elicited by previous infections with other coronaviruses. To investigate this possibility, we assayed the complete sample panel for IgG antibodies binding to the C-terminal dimerization domains of the four common cold coronavirus NCPs using an in-house IgG ELISA protocol ((14), **Appendix Methods**, **Figure 2B-E**).

88 As can be expected due to the worldwide occurrence of the common cold coronaviruses, IgG 89 antibodies interacting with the C-terminal domains of OC43, HKU1, NL63, and 229E NCP 90 were detected in considerable fractions of all sample panels, including those for which good 91 or excellent SARS-CoV-2 ELISA specificity has been observed (Figure 2B-E). Nevertheless, 92 the most challenging sample panel originating from Nigerian donors displayed the by far 93 highest percentage of OC43-ELISA-reactive samples (43.3 %, Figure 2B). In a line blot 94 (Euroline Anti-SARS-CoV-2 Profile IgG, Euroimmun), all 15 serum samples from Ghana 95 (n=7) and Nigeria (n=8) showing up positive in both the spike/S1-based and the NCP-based 96 Euroimmun IgG ELISA generated strong signals with OC43 NCP (Figure 2A). In addition,

antibodies binding to SARS-CoV-2 spike S2 were found in 6/7 Ghanaian and 3/8 Nigerian
samples (Figure 2A). 7/8 of the Nigerian sera, but only 2/7 of the Ghanaians samples tested
positive in the in-house OC43 ELISA employing a truncated NCP lacking the N-terminal
domain as antigen. Therefore, at least some of the observed false positive signals could be
due to previous infections with other coronaviruses sharing B cell epitopes with both OC43
and SARS-CoV-2.

103 Recently, Lustig *et al. (11)* reported false positive results of the Euroimmun Anti-SARS-CoV-104 2 IgA and IgG ELISAs in sera originating from donors with acute or past dengue virus 105 (DENV) infection. In our study, 29 (21.6%) of the 134 Colombian donors tested positive in the 106 SD Bioline Dengue Duo IgG Rapid Test (Alere/Abbott, USA), indicating a high titer of anti-107 DENV IgG antibodies (15). Indeed, two of the three Colombian sera testing positive in the 108 spike-based Euroimmun Anti-SARS-CoV-2 ELISA (but negative in the nucleoprotein-based 109 SARS-CoV-2 ELISAs) belonged to this subgroup.

110 In addition, hypergammaglobulinemia resulting from polyclonal B-cell activation induced by 111 pathogens like plasmodium can challenge assay specificity as has already been shown for a 112 commercially available ZIKV IgG ELISA (12). Information about Plasmodium parasitemia 113 was only available for one of the Ghanaian (55/150 samples with microscopically detectable 114 parasitemia) and the Madagascan (4/167 Plasmodium-PCR positive samples) panels. Here, 115 a reduced specificity in Ghanaian parasitemic vs. non-parasitemic samples was observed for 116 the Euroimmun Anti-SARS-CoV-2-NCP-IgG ELISA (83.6% (95% CI: 71.5%-91.4%) vs. 117 94.7% (95% CI: 88.0%-98.0%), p = 0.0387), but not for the other SARS-CoV-2 IgG ELISAs 118 (Appendix Table 2).

119

120 LIMITATIONS OF THE STUDY

Our study has some major limitations that have to be acknowledged when interpreting the presented data. First of all, sample panels originating from previous studies with different scientific objectives had to be used for the analysis; therefore, the panels do not reflect representative cross-sections of the respective countries' populations and also comparability between sample panels is limited due to differences in age and sex of donors. Although in total 600 African samples have been analyzed, the number of samples per country giving rise to false positive SARS-CoV-2 IgG assay results is still relatively small, impeding statistical analyses. Furthermore, limited accessible sample volumes prevented us from performing material-intensive assays as the SD Bioline Dengue Duo IgG Rapid Test or *Plasmodium*-specific RT-PCR for the complete panel.

131

132 CONCLUSIONS

In accordance with evaluation studies recently published by other authors (4-6), the 133 134 commercially available SARS-CoV-2 IgG ELISAs displayed a good to excellent specificity 135 when applied to serum panels originating from European donors. In contrast, significantly 136 increased false positive rates were observed in African pre-COVID-19 serum panels 137 originating from Ghana and Nigeria. A similar result has been found recently for serum 138 samples from febrile patients from Benin (9). Possible causes for this observation are cross-139 reactive antibodies elicited by previous infections with endemic viruses (in particular other 140 coronaviruses), polyclonal B-cell activation induced e.g. by plasmodium infection, or a 141 combination thereof.

142 Based on these findings, the following recommendations should be considered when 143 planning and performing SARS-CoV-2 seroprevalence studies (not only) in Africa: 1) Prior to 144 performance of seroprevalence studies, carefully assess background/false positive signals 145 obtained with the chosen serological test(s) in the target population (using a priori SARS-146 CoV-2 IgG negative serum samples which were stocked before 2019). Be aware of 147 potentially interfering/cross-reacting endemic pathogens and carefully interpret SARS-CoV-2 148 IgG test results in this context. 2) If necessary, combine information from two independent 149 serological tests employing different antigens. 3) Re-evaluate samples generating a positive 150 ELISA result by SARS-CoV-2 neutralization testing.

- Further studies will be necessary to assess sensitivity of the commercially available assays in detecting anti-SARS-CoV2 IgG antibodies induced by SARS-CoV-2 infection in African COVID-19 patients and to optimize assay specificity in sera from African donors.
- 154

155 **ACKNOWLEDGMENTS**

The authors thank M. Panning for providing common cold coronavirus RNAs. J. Hansen isthanked for expert technical assistance.

158

159 FUNDING

160 The study was supported by the German Federal Ministry of Education and Research (Grant 161 no. 01KI20210), the German Research Foundation (DFG, GU 883/4-1 and GU 883/5-1), by 162 the German Federal Ministry of Health through support of the WHO Collaborating Centre for 163 Arboviruses and Hemorrhagic Fever Viruses at BNITM (agreement ZMV I1-2517WHO005), 164 through the Global Health Protection Program (agreement ZMV I1-2517GHP-704), and 165 through the COVID support agreement ZMVI1-2520COR001. Collection of Colombian serum 166 samples was supported by the European Regional Development Fund (ERDF), project 167 number BWF/H/52228/2012/13.10.10-1/3.4. The funders had no role in study design, data 168 collection and analysis, decision to publish, or preparation of the manuscript.

169

170 AUTHOR BIOGRAPHY

Dr. Emmerich is a laboratory group leader at the Bernhard Nocht Institute for Tropical
Medicine in Hamburg, Germany. Her research is focused on diagnostics of viral infectious
diseases.

174 **REFERENCES**

- 175 1. WHO. COVID-19 Weekly Epidemiological Update, 01Nov2020
- 176 2. FIND. https://www.finddx.org/covid-19/sarscov2-eval-immuno/
- 177 3. University JH. https://www.centerforhealthsecurity.org/resources/COVID-
- 178 19/serology/Serology-based-tests-for-COVID-19.html. 2020.
- 179 4. Geurts van Kessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM,
- 180 et al. An evaluation of COVID-19 serological assays informs future diagnostics and
- 181 exposure assessment. Nature communications. 2020;11(1):3436.
- 182 5. Kruttgen A, Cornelissen CG, Dreher M, Hornef M, Imohl M, Kleines M. Comparison of
- 183 four new commercial serologic assays for determination of SARS-CoV-2 IgG. Journal
- 184 of clinical virology : the official publication of the Pan American Society for Clinical
- 185 Virology. 2020;128:104394.
- Pflüger LS, Bannasch JH, Brehm TT, Pfefferle S, Hoffmann A, Nörz D., et al. Clinical
 evaluation of five different automated SARS-CoV-2 serology assays in a cohort of
- 188 hospitalized COVID-19 patients. Journal of Clinical Virology. 2020.
- 189 7. Weidner L, Gansdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M, et al.
- 190 Quantification of SARS-CoV-2 antibodies with eight commercially available
- 191 immunoassays. Journal of clinical virology : the official publication of the Pan
- 192 American Society for Clinical Virology. 2020;129:104540.
- 193 8. Chibwana MG, Jere KC, Kamn'gona R, Mandolo J, Katunga-Phiri V, Tembo D, et al.
- High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers
 of deaths in urban Malawi. MedRxiv preprint,
- 196 https://doi.org/10.1101/2020.07.30.20164970. 2020.
- 197 9. Yadouleton A, Sander A, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, et al.
- 198 Limited specificity of serologic tests for SARS-CoV-2 antibody detection, Benin,
- 199 Western Africa. medRxiv preprint, https://doi.org/10.1101/2020.06.29.20140749.
- 200 2020.

- 201 10. Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J., et al. High
- 202 prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-
- 203 Saharan Africa. International Journal of Infectious Diseases.
- 204 https://doi.org/10.1016/j.ijid.2020.10.104. 2020
- 205 11. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential
- antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses. Clin Infect Dis.
 207 2020.
- 208 12. Van Esbroeck M, Meersman K, Michiels J, Arien KK, Van den Bossche D. Letter to
- 209 the editor: Specificity of Zika virus ELISA: interference with malaria. Euro surveillance
- 210 : bulletin Europeen sur les maladies transmissibles = European communicable

211 disease bulletin. 2016;21(21).

- 212 13. Reisinger EC, von Possel R, Warnke P, Geerdes-Fenge HF, Hemmer CJ, Pfefferle S,
- 213 et al. Screening of Mothers in a COVID-19 Low-Prevalence Region: Determination of
- 214 SARS-CoV-2 Antibodies in 401 Mothers from Rostock by ELISA and Confirmation by

215 Immunofluorescence. Deutsche medizinische Wochenschrift. 2020.

- 216 14. Schmitz H, Gabriel M, Emmerich P. Specific detection of antibodies to different
- 217 flaviviruses using a new immune complex ELISA. Med Microbiol Immunol.
- 218 2011;200(4):233-9.
- 219 15. Blessmann J, Winkelmann Y, Keoviengkhone L, Sopraseuth V, Kann S, Hansen J, et
 220 al. Assessment of diagnostic and analytic performance of the SD Bioline Dengue Duo
- test for dengue virus (DENV) infections in an endemic area (Savannakhet province,
- Lao People's Democratic Republic). PLoS One. 2020;15(3):e0230337.

223

224 TABLES

225

serum panel Ghana 1		Ghana 2	Madagascar	Nigeria	Colombia	Germany	
number	150	133	167	150	134	148	
sampling year	2014 - 2015	1999	2010	2018	2014	2004 - 2015	
sample type	sample type serum seru		plasma	serum	serum	serum	
donors	children	teens, adults	pregnant women	adults	adults	adults	
age (median, IQR)	6 (3 – 7)	22 (16 – 45) *	23 (20 – 30)	41 (30 – 58)**	27 (23 – 36)	39 (28 – 48)***	
sex m/f (n (%))	72/78 (48/52)	61/72 (46/54)	0/167 (0/100)	71/79 (47/53)	55/79 (41/59)	79/35 (69/31)***	
sampling site	ite Agogo village: central Ghana		coastal (n=89) and highland (n=68) regions	Irrua	Valledupar	Hamburg	
<i>Plasmodium spp.</i> positive (n (%))	lasmodium spp. 55 (37.7 %) [#] not tested ositive (n (%))		4 (2.4%) *	not tested	not tested; no previous infec- tions reported	not tested	
SD Bioline Dengue Duo Rapid Test IgG pos (n (%))	SD Bioline Dengue not tested not test Duo Rapid Test IgG pos (n (%)) Igg pos (n (%))		not tested	not tested	29 (21.6%)	not tested	

226 Table 1. Sample panels used in the study

227

228 M: male, f: female, IQR: interguartile range.

229 Collection of samples has been approved by the Ethics Committees of the Kwame Nkrumah 230 University of Science and Technology (Kumasi/Ghana), the Comité d'ethique de la Vice 231 Primature Chargée de la Santé Publique (Antananarivo/Madagaskar), the Irrua Specialist 232 Teaching Hospital (Irrua/Nigeria), the Hospital Rosario Pumarejo de Lopez 233 (Valledupar/Colombia), and the Medical Association Hamburg/Germany. All studies complied 234 with the Declaration of Helsinki. Written informed consent was obtained from all individuals 235 or, in case of minors, from parents or legal guardians before enrollment. Data privacy 236 protection was guaranteed by anonymization of samples.

237 *n=89 (exact age information not available for 43 donors (all 43: age \geq 18 years))

- 238 **n=149 (age information not available for one donor)
- 239 ***n=114 (sex and exact age information not available for 34 donors (all 34: age \geq 18 years))
- 240 [#]Parasitemic samples were identified by microscopy (Ghana) and plasmodium-specific RT-
- PCR (Madagascar), respectively. 241
- 242
- 243
- 244

245 Table 2. SARS-CoV-2 IgG ELISA specificities

				Euroimmun Anti- SARS-CoV-2-NCP- ELISA IgG			Euroimmun Anti- SARS-CoV-2-ELISA IgG			<i>EDI</i> [™] Novel Coronavirus COVID- 19 IgG ELISA kit			Mikrogen <i>recom</i> Well SARS-CoV-2 lgG		
Antigen			NCP	(modif	ied)	Spike S1 domain			NCP			NCP			
Ghana 1	pos	bl	neg	14	11	125	12	1	137	24	17	109	7	7	136
(n=150)	specificity (95% CI)			90.7 (84.8 - 94.5)			92.0 (86.4 - 95.5)			84.0 (77.2 – 89.1)			95.3 (90.5 - 97.9)		
Ghana 2	pos	bl	neg	34	21	78	4	3	126	39	15	79	22	10	101
(n=133)	specificity (95% CI)			74.4 (66.4 - 81.1)			97.0 (92.3 – 99.1)			70.7 (62.4 – 77.8)			83.5 (76.2 - 88.9)		
Madagas-	pos	bl	neg	2	4	161	3	0	164	11	10	146	1	3	163
car (n=167)	specificity (95% CI)			98.8 (95.5 - 99.9)			98.2 (94.6 – 99.6)			93.4 (88.5 - 96.4)			99.4 (96.3 - 100.0)		
Nigeria	pos	bl	neg	42	18	90	14	7	129	91	19	40	26	6	118
(n=150)	specifi	city (95	5% CI)	72.0 (64.3 – 78.6)			90.7 (84.8 - 94.5)			39.3 (31.9 – 47.3)			82.7 (75.8 – 87.9)		
Colombia	pos	bl	neg	0	1	133	3	1	130	1	3	130	3	2	129
(n=134)	specificity (95% CI)			100.0 (96.6 - 100.0)			97.8 (93.3 – 99.5)			99.2 (95.5 – 100.0)			97.8 (93.3 – 99.5)		
Germany	pos	bl	neg	0	4	144	2	3	143	2	1	145	6	0	142
(n=148)	specificity (95% CI)		100.0 (97.0 - 100.0)			98.6 (94.9 - 99.9)			98.6 (94.9 - 99.9)			95.9 (91.2 – 98.3)			

246

247 pos/bl/neg: number of samples rated as positive (pos), borderline (bl), and negative (neg) by

248 the respective test. CI: confidence interval. For calculation of specificities, both negative and

249 borderline results were classified as "not positive".

250 FIGURE LEGENDS

251

252 Figure 1. SARS-CoV-2 IgG ELISA results. Index values obtained for serum/plasma 253 samples collected before 2019 in three different African countries (Ghana panel 1 (n=150), 254 Ghana panel 2 (n=133), Madagascar (n=167), Nigeria (n=150)), Colombia (n=134), and 255 Germany (n=148) with (A) the Euroimmun Anti-SARS-CoV-2-NCP IgG ELISA, (B) the 256 Euroimmun Anti-SARS-CoV-2 IgG ELISA, (C) the EDI Novel Coronavirus COVID-19 IgG 257 ELISA, and (D) the Mikrogen recomWell SARS-CoV-2 IgG ELISA. Dotted lines represent 258 negative and positive cut-off values, respectively. Grey shading indicates index values rated 259 as "borderline" according to the manufacturers' instructions. Diamonds represent index 260 values obtained for two IgG positive COVID-19 patient sera sampled on day 19 post onset of 261 symptoms (dark grey: SARS-CoV-2 IgG IIFT titer 1:640, light grey: SARS-CoV-2 IgG IIFT 262 titer 1:160) and one negative control serum; error bars represent standard deviation of n=13 263 (A, C) and n=14 (B, D) independent measurements, respectively.

264

Figure 2. (A) ELISA, sVNT and line blot results for sera testing positive in both the 265 266 Euroimmun spike/S1- and NCP-based IgG ELISA. Serum samples (Ghana 1 (G1): n=4, 267 Ghana 2 (G2): n=3, Nigeria (N): n=8)) were tested using the SARS-CoV-2 sVNT (Genscript) 268 and the Euroline Anti-SARS-CoV-2 Profile IgG (Euroimmun) according to the manufacturer's 269 instructions. Rating of index values (iv): Euroimmun ELISA: negative: iv < 0.8, borderline; 0.8 270 \leq iv < 1.1, positive: iv \geq 1.1; Line blot: negative: iv < 0.6, borderline: 0.6 \leq iv < 1.0, positive: iv 271 \geq 1.0; in-house ELISA: negative: iv < 0.7, borderline: 0.7 \leq iv < 1.3, positive: iv \geq 1.3; sVNT: 272 negative: % inhibition < 20.0, borderline; $20.0 \le \%$ inh < 30.0, positive: % inh ≥ 30.0 ; CTD: C-273 terminal domain; dark grey fields: positive; light grey fields: borderline. (B) - (E) Common 274 cold CoVs ELISA results. Index values obtained for the sample panels from Ghana (1: 275 n=150, 2: n=133), Madagascar (n=167), Nigeria (n=150), Colombia (n=134), and Germany 276 (n=148) using an in-house IgG ELISA protocol employing the C-terminal dimerization domain 277 of (A) OC43 NCP, (B) HKU1 NCP, (C) NL63 NCP, and (D) 229E NCP as antigen. Bold

- 278 numbers: % of samples for which an iv \geq 1.3 was obtained, numbers in brackets: 95%
- 279 confidence interval. Grey shading indicates ivs rated as "borderline" ($0.7 \le iv < 1.3$).

Figure 1



medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20159749; this version posted December 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Figure 2

Α

ID	sVNT % inh	Euroimmun ELISA		Euroimmun Lineblot								in-house ELISA			
		SARS	-CoV-2	SARS-CoV-2			NCP				NCP-CTD				
		NCP	S1	NCP	S1	S2	OC43	HKU1	NL63	229E	OC43	HKU1	NL63	229E	
G1-1	1.9	1.2	2.0	0.4	3.1	3.5	5.0	0.7	0.1	0.1	1.5	0.5	0.1	0.1	
G1-2	9.4	2.7	4.6	0.9	5.3	5.2	6.2	0.5	0.4	0.2	0.4	0.3	0.2	0.2	
G1-3	10.0	1.4	2.5	1.1	3.6	1.9	5.1	0.2	0.6	0.5	0.2	0.2	0.3	0.2	
G1-4	4.1	2.5	1.9	0.5	1.6	2.4	4.1	0.9	2.8	1.2	2.9	0.3	10.1	0.2	
G2-1	25.6	1.8	1.2	0.9	1.0	0.6	1.6	0.2	0.3	0.4	0.6	0.2	0.2	0.1	
G2-2	24.6	1.5	1.9	0.9	1.7	2.2	7.1	0.4	2.1	0.9	0.2	0.3	2.0	0.1	
G2-3	21.2	1.3	1.2	1.4	2.4	4.3	7.3	0.2	0.8	0.2	0.2	0.3	0.2	0.1	
N-1	24.4	3.6	1.8	3.7	1.3	1.0	5.3	0.3	1.0	2.8	5.3	0.2	6.0	0.2	
N-2	10.7	4.9	1.3	2.3	0.4	0.3	6.2	0.4	1.4	0.5	1.5	0.2	0.2	0.2	
N-3	23.7	4.4	7.7	1.1	6.8	5.6	7.2	2.7	1.4	0.8	7.5	2.8	0.6	0.3	
N-4 N-5 N-6	28.4 19.4 21.5	4.9 2.6 2.1	1.5 1.4 2 1	3.3 0.3 1.2	1.8 0.7 1.6	0.8 0.2	4.1 5.8 4.2	1.0 0.5 0.3	3.0 1.1 0.7	2.2 0.7 3.5	1.4 1.5 4 3	0.6 0.4	7.4 0.3 1.1	0.3 0.2 2.6	
N-7	27.7	1.7	2.2	1.3	2.2	2.3	5.1	0.9	1.5	0.7	7.4	2.9	9.8	2.0	
N-8	28.3	1.4	1.2	0.4	1.0	0.3	5.0	1.0	1.2	0.7	1.0	0.7	0.9	0.3	

OC43 Β

Nadagascat

Colombia

Germany

t Nigeria

Chara²

Ghana¹



Ghana¹

Chara²

Nadagascat

Colombia

1 Nigeria

1 Germany